Skip to main content

Pretreatment with sufentanil reduces myoclonus after etomidate

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Background:

Myoclonic movements are a common problem during the induction of general anesthesia with etomidate. We investigated the influence of pretreatment with the opioid sufentanil on the incidence of etomidate-induced myoclonus. Methods:

Forty female patients (ASA physical status I–III) were randomly assigned to receive double-blinded either 0.3 µg kg−1 of sufentanil or placebo 150 s before the induction of sleep with 0.3 mg kg−1 of etomidate. The patients were observed for any myoclonic movement. Grade of dizziness, breathing frequency, non-invasive blood pressure and heart rate were measured during the study period. Results:

None of the 20 patients receiving sufentanil had myoclonic movements after the administration of etomidate, whereas 16 patients in the placebo group (80%) experienced such movements (P<0.01). No cases of apnoea before induction of sleep were seen in the sufentanil group. Conclusion:

Sufentanil 0.3 µg kg−1 is an effective and safe drug to reduce myoclonus after etomidate without causing any harmful side-effect.

Keywords: adverse effects; anesthetics; etomidate; myoclonus; sufentanil

Document Type: Research Article

DOI: http://dx.doi.org/10.1034/j.1399-6576.2003.00081.x

Affiliations: 1: Klinik fuer Anesthesiologie und Intensivtherapie, Friedrich-Schiller-Universitaet Jena, Germany, 2: Department of Kinesiology, University of Wisconsin, WI

Publication date: April 1, 2003

mksg/aas/2003/00000047/00000004/art00019
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more